Institutional Review Boards Frequently Asked Questions Guidance for Institutional Review Boards and Clinical Investigators-2025/2/5

Institutional Review Board (IRB) Written Procedures-2025/2/5

Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)-2025/1/31

Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)-2025/1/31

Bioanalytical Method Validation for Biomarkers-2025/1/21

Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology-2025/1/17

Premarket Approval Application and Humanitarian Device Exemption Modular Review-2025/1/13

Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction-2025/1/7

Developing Drugs for Optical Imaging-2025/1/7

CVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process-2025/1/7